Home » Stocks » GMDA

Gamida Cell Ltd. (GMDA)

Stock Price: $5.21 USD -0.47 (-8.27%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $5.34 +0.13 (2.50%) Jul 26, 7:14 PM
Market Cap 336.26M
Revenue (ttm) n/a
Net Income (ttm) -101.53M
Shares Out 59.20M
EPS (ttm) -1.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $5.21
Previous Close $5.68
Change ($) -0.47
Change (%) -8.27%
Day's Open 5.64
Day's Range 5.21 - 5.65
Day's Volume 448,519
52-Week Range 3.86 - 15.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the results of a Ph...

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that company management will p...

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced the appointment of Vladimir Me...

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph. D., chi...

2 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today reported financial results for the quart...

2 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a c...

2 months ago - Business Wire

ARR, GMDA, ISEE, LMB, and LIQT have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2021

Other stocks mentioned: ARR, ISEE, LIQT, LMB
3 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph. D., chi...

3 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the results of a Phase 3...

4 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today reported financial results for t...

4 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that company management will p...

4 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a c...

4 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that results from the Ph...

4 months ago - Business Wire

Recent clinical readouts could prove to be long-term growth catalysts for Novavax and Gamida Cell.

Other stocks mentioned: NVAX
5 months ago - The Motley Fool

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to developing and commercializing cures for blood cancers and serious hematologic diseases, today ann...

5 months ago - Business Wire

The company released data from a late-stage clinical trial.

5 months ago - The Motley Fool

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the results of a Phase 3...

5 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the full results of...

6 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that company management will p...

6 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that its previously anno...

7 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that it has been selecte...

7 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the pricing of a follow-...

7 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the launch of a follow-o...

7 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the company conduct...

7 months ago - Business Wire

Early data for this company's natural killer cells is drawing lots of attention.

7 months ago - The Motley Fool

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today will be providing an update on the...

7 months ago - Business Wire

Gamida Cell (NASDAQ: GMDA) shares are trading higher on Monday following the company's Saturday GDA-201 presentation at the American Society of Hematology Annual Meeting. Gamida Cell is a biopharmaceuti...

Other stocks mentioned: HOOK
7 months ago - Benzinga

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced in an oral presentation ...

7 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that it will host a virtual ev...

7 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Chief Execu...

8 months ago - Business Wire

Gamida Cell Ltd (GMDA) CEO Julian Adams on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today reported financial results for t...

8 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that updated data from the ongoing Phase 1 clinical study of GDA-201, an inv...

8 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph. D., chi...

8 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell announced that it will report its third quarter 2020 financial results and provide a company update on November 10, 2020.

8 months ago - Business Wire

Gamida Cell recently executed a secondary at $4.50 a share on the back of positive Phase 3 clinical data for its lead asset. The cell therapy biotech now trades at half its 2018 post IPO price despite a...

8 months ago - Seeking Alpha

BOSTON & MINNEAPOLIS--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell and Be The Match BioTherapies® today announced an expansion of their strategic collaboration for investigational omidubicel.

9 months ago - Business Wire

Gamida Cell (GMDA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell will present at the annual Cell & Gene Meeting on the Mesa to be held virtually October 12 - 16, 2020.

9 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell announced that its Phase 3 clinical study of omidubicel in bone marrow transplant met all three secondary endpoints.

9 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell today announced data from an observational study being presented at the virtual Cord Blood Connect Meeting.

10 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $GMDA--Gamida Cell will participate in three upcoming virtual investor conferences in September.

10 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell will host a two-part virtual miniseries in September focused on key topics related to its investigational cell therapy omidubicel.

10 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $GMDA--Gamida Cell will webcast its Annual Meeting of Stockholders on Thursday, September 10, 2020, at 10:00 a.m. ET.

11 months ago - Business Wire

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Shares of Gamida Cell (NASDAQ:GMDA) moved higher by 1.6% in pre-market trading after the company reported Q2 results.

11 months ago - Benzinga

Gamida Cell (GMDA) will provide updates on its pipeline candidates when it releases second-quarter 2020 results.

1 year ago - Zacks Investment Research

Is (GMDA) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Gamida Cell (GMDA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for May 28th

Other stocks mentioned: AAWW, AXU, NCNA
1 year ago - Zacks Investment Research

About GMDA

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and mu... [Read more...]

Industry
Biotechnology
IPO Date
Oct 26, 2018
Stock Exchange
NASDAQ
Ticker Symbol
GMDA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Gamida Cell stock is "Buy." The 12-month stock price forecast is 19.00, which is an increase of 264.68% from the latest price.

Price Target
$19.00
(264.68% upside)
Analyst Consensus: Buy